New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
05:10 EDTSGYPSynergy announces possitive results from plecanatide Phase IIb/III trial
Synergy Pharmaceuticals announced that plecanatide, its investigational oral drug for the treatment of chronic idiopathic constipation, or CIC, was well tolerated and met the primary and key secondary endpoints of a Phase IIb/III clinical study. Full study results will be presented at a major scientific meeting this year. The randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study was designed to determine whether plecanatide could increase the number of complete spontaneous bowel movements, or CSBM's, and impact other parameters such as stool consistency, straining and time to first bowel movement in patients with CIC. The 12-week study, which included 951 CIC patients at 113 clinical sites in the United States, evaluated 3 doses of plecanatide plus a placebo arm. Evidence of increasing efficacy was seen at increasing dose levels. Notably, the 3 mg dose in the current trial demonstrated a 19% overall responder rate, as well as demonstrating a mean increase in CSBMs over the 12-week treatment period of 2.13. In addition, statistically significant improvements were seen in key secondary endpoints. The incidence of diarrhea at 3 mg was observed to be 9.7% .
News For SGYP From The Last 14 Days
Check below for free stories on SGYP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
09:10 EDTSGYPSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Synergy Pharmaceuticals' (SGYP) Plecanatide for Irritable Bowel Disease with constipation on an Analyst/Industry conference call to be held on April 17 at 11 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use